Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

News Centre

  • ESMA Publishes Its Report On The Use Of FinTech By CSDs

    Date 06/08/2021

    The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, has today published its Report on the use of FinTech by Central Securities Depositories (CSDs).

  • Moscow Exchange: Risk Parameters Change For The Securities

    Date 06/08/2021

    The following risk parameters will be changed:

    TickerIR risk (downward scenario) - SECΔ_1 (Y0/Y1)New value effective for
    Current valueNew value
    JNJ-RM 35% 77% 20.08.2021 - 24.08.2021
    MAGN 35% 77% 12.08.2021 - 16.08.2021
    EMR-RM 35% 77% 11.08.2021 - 13.08.2021

  • Bitfinex Launches BIT Mode On Satoshi

    Date 06/08/2021

    Bitfinex, a state-of-the-art digital token trading platform, has made BIT Mode on Satoshi available to the exchange’s user base, enabling customers to divide their holdings into the smallest units of a bitcoin.

  • Ulisse Biomed S.p.A. Lists On AIM Italia

    Date 06/08/2021

    • Twenty–second listing of 2021 on Borsa Italiana’s AIM Italia
    • Ulisse Biomed S.p.A. brings the total number of companies listed on Borsa Italiana’s AIM Italia to 153
    • Total placement volume of the offering equal to €5 million with listing

  • Borsa İstanbul’s Opening Bell Rang For Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.

    Date 06/08/2021

    In his address at the opening bell ceremony, Borsa İstanbul CEO Korkmaz Ergun contended as follows:

    “Ladies and gentlemen, I welcome you all to the ceremony held for the Initial Public Offering (IPO) of Gen İlaç. First of all, due to the forest fire we are facing, I would like to express that we stand by all of our officers and people who are struggling with full effort as Borsa İstanbul. I wish God's mercy on those who lost their lives and a speedy recovery to all the injured. Gen İlaç makes us all proud in the pharmaceutical industry with its qualified product and service approach. Once again, it has been understood during the pandemic that the breakthroughs of our companies such as Gen İlaç will continue to carry our country a step further in this strategically important sector. Thus, the place and significance of Gen İlaç in the sector and its accomplishments in its activities also resonate with the success of the IPO. Gen İlaç launched a successful IPO with an amount of approximately 738 million TL and sales to 49 thousand investors.